Clinical Trials Directory

Trials / Completed

CompletedNCT00214955

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Neuropathic Pain

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
120 (planned)
Sponsor
Cephalon · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Neuropathic Pain

Conditions

Interventions

TypeNameDescription
DRUGORAVESCENT Fentanyl Citrate

Timeline

Start date
2005-09-01
Primary completion
2006-05-01
First posted
2005-09-22
Last updated
2014-05-09

Locations

17 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00214955. Inclusion in this directory is not an endorsement.